Product code QWR— Microbiology

ID NOW COVID-19 2.0

Classification name
Simple Point-Of-Care Device To Detect Sar-Cov-2 Nucleic Acid Targets From Clinical Specimens In Near-Patient Settings
Device class
Class 2
Regulation
21 CFR 866.3982
Advisory panel
Microbiology
Total cleared
3
First cleared
Most recent

FDA classification definition

“A simple point-of-care device to detect SARS-CoV-2 nucleic acid targets directly from clinical specimens in near-patient settings is an in vitro diagnostic device for the direct detection of SARS-CoV-2 in clinical specimens and is intended as an aid in the diagnosis of SARS-CoV-2 infections (COVID-19). The device is simple to use and does not involve sample manipulation, transportation of the sample to another functional area (e.g., a central laboratory or other specialized area), or measurement of reagents or analytes that could be affected by conditions such as sample turbidity or cell lysis. The design and procedures of the device are appropriate for use by healthcare professionals in near-patient settings outside a centralized laboratory.”

— U.S. Food and Drug Administration, device classification record for product code QWR under 21 CFR 866.3982, via openFDA

Market context for product code QWR

FDA has cleared 3 devices under product code QWR between 2023 and 2025, filed by 2 applicant companies. No FDA device recalls reference this product code. Class II devices are moderate-risk and subject to general and special controls; most reach market through 510(k) clearance by demonstrating substantial equivalence to a predicate device.

Clearances per year

Top applicants under product code QWR

Recent clearances under product code QWR

Data sourced from openFDA. This site is unofficial and independent of the FDA.